Fig. 2: Absence of NLRP3 reverses the effects of KrasG12D in peripheral blood.
From: Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
a Schematic diagram summarizing the experimental plan for generating BM chimeras that have WT BM, KrasG12D BM or KrasG12D; Nlrp3−/− BM. b The percentage of hematocrit in PB of WT (n = 10), KrasG12D (n = 15) and KrasG12D; Nlrp3−/− (n = 10) BM mice. c The concentrations of hemoglobin in PB of WT (n = 10), KrasG12D (n = 15) and KrasG12D; Nlrp3−/− (n = 10) BM mice. d The percentage of immature red blood cells observed in PB of WT (n = 10), KrasG12D (n = 8) and KrasG12D; Nlrp3−/− (n = 9) BM mice. e Representative PB smears images showing the increase in immature blood cells (marked with yellow arrows) in KrasG12D BM mice, as compared to WT and KrasG12D; Nlrp3−/− BM mice (Scale bar, 100 µm). The images are representative for three independent experiments. f Platelet counts in the PB of WT (n = 10), KrasG12D (n = 15) and KrasG12D; Nlrp3−/− (n = 10) BM mice are shown. g Representative PB smear image showing the enlarged size of platelets in KrasG12D BM mice (Scale bar, 10 µm). h The number of giant platelets counted in PB smears of WT (n = 10), KrasG12D (n = 15) and KrasG12D; Nlrp3−/− (n = 10) BM mice. All data are shown as mean ± SEM.
